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The ability to track cells and their patterns of gene expression in
living organisms can increase our understanding of tissue devel-
opment and disease. Gene reporters for bioluminescence, fluores-
cence, radionuclide, and magnetic resonance imaging (MRI) have
been described but these suffer variously from limited depth
penetration, spatial resolution, and sensitivity. We describe here
a gene reporter, based on the organic anion transporting protein
Oatp1a1, which mediates uptake of a clinically approved, Gd3+-
based, hepatotrophic contrast agent (gadolinium-ethoxybenzyl-
diethylenetriamine pentaacetic acid). Cells expressing the reporter
showed readily reversible, intense, and positive contrast (up to
7.8-fold signal enhancement) in T1-weighted magnetic resonance
images acquired in vivo. The maximum signal enhancement
obtained so far is more than double that produced by MRI gene
reporters described previously. Exchanging the Gd3+ ion for the
radionuclide, 111In, also allowed detection by single-photon emis-
sion computed tomography, thus combining the spatial resolution
of MRI with the sensitivity of radionuclide imaging.
SPECT | Oatp
The development of noninvasive imaging techniques to trackcells and their patterns of gene expression in vivo has been
a much sought-after goal as it enables imaging of various bi-
ological phenomena including stem and immune cell migration,
delivery and expression of gene therapy vectors, the genetics of
development, and the progression of diseases such as cancer and
their response to treatment (1, 2).
Bioluminescent and fluorescent reporters (3, 4), though sen-
sitive, suffer from limited light penetration in whole animal studies
and consequently have relatively poor spatial resolution (5). Ra-
dionuclide imaging reporters (1) have good sensitivity and depth
penetration but lack spatial resolution (5), whereas magnetic
resonance imaging (MRI) reporters (6) have good depth pene-
tration and relatively good resolution but currently lack sensi-
tivity and produce poor tissue contrast (7). Table S1 describes
the published gene reporters that have been developed for MRI.
Apart from the magnetic resonance (MR) spectroscopy report-
ers, which lack spatial resolution, the majority of MRI gene
reporters rely on negative contrast (T2 enhancing agents), which
can be difficult to detect in a heterogeneous image. The most
promising of these, ferritin (6), gives only modest contrast (Table
S1) and has led to calls for reporters with increased sensitivity
(8). Deans et al. increased ferritin sensitivity by coexpressing the
transferrin receptor and incubating the cells with iron and
transferrin in the culture medium (9). However, despite the use
of a vector designed to give high level constitutive expression, the
R2 relaxation rate (1/T2) increased by only a factor of ∼2 at 7 T
and was not significant at 1.5 T. Of the positive contrast agents
(T1 enhancing agents), which are easier to detect in vivo, the
divalent metal ion transporter (DMT1), which transports Mn2+,
and a metabolically biotinylated cell surface protein [biotin ac-
ceptor peptide (BAP)-transmembrane (TM)], which was detec-
ted using a streptavidin–horseradish peroxidase (SA-HRP)
conjugate in conjunction with a peroxidase-sensitive gadolinium
agent (10), have so far given the best contrast in vivo. However,
DMT1 gave only a 75% increase in image contrast in glioma
tumors transfected with a vector expressing DMT1 from a strong
constitutive promoter (11). Moreover, there was significant en-
hancement in surrounding normal tissue and the persistence of
the enhancement varied markedly between different tumor types.
BAP-TM gave better contrast [3.3× enhancement in a s.c. glioma
tumor, where the protein was expressed from the strong cyto-
megalovirus (CMV) promoter]. However, this first required in-
jection of the macromolecular agent, SA-HRP, which would
preclude human use and whose large size may limit tissue access
and then, when this had cleared, the gadolinium agent was
injected. There was no evidence that this system was quantitative.
An ideal gene reporter would give fast, reversible, quantita-
tive, and intense gene expression-dependent contrast and would
work with multiple imaging modalities, thus combining their
different advantages. One approach to this has been to create
fusion proteins, for example between luciferase, red fluorescent
protein (RFP), and thymidine kinase, which allows imaging with
bioluminescence, fluorescence, and positron emission tomogra-
phy (PET), respectively (12). A limitation is that the fusion
protein may not be as well expressed or have the same activity as
the individual proteins and the large size of the DNA construct
may preclude its incorporation into some vectors. An elegant
solution to this problem was reported recently by Niers et al.
(13), who expressed, from a strong constitutive promoter, a
metabolically biotinylated, membrane-bound form of Gaussia
luciferase in an implanted glioma tumor. The reporter could
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be detected using bioluminescence, following injection of coe-
lenterazine, and by fluorescence tomography, MRI, and single-
photon emission computed tomography (SPECT), following in-
jection of streptavidin conjugated to a fluorophore, magnetic
nanoparticles, and 111In- diethylenetriamine pentaacetic acid
(DTPA), respectively. Although the reporter is small (∼40 kDa)
the imaging agents are large (the magnetic nanoparticles were ∼45
nm in diameter), the MR image contrast was negative and modest
(∼2× increase in R2 in vivo) and there was no evidence that it was
reversible, which may limit longitudinal studies of gene expression.
We describe here a gene reporter system in which the dual-
modality imaging capability (MRI and SPECT) is invested in
a single protein, Oatp1a1 (Slco1a1, Slc21a1, Slc21a3, Oatp1,
Oatp1a1, OATP-1). This protein from the SLCO superfamily
(14) has the capacity to transport a variety of imageable small
molecules across the plasma membrane. These include the clini-
cally approved hepatobillary MRI contrast agent, gadolinium-
ethoxybenzyl-DTPA (Gd-EOB-DTPA; gadoxetate or Primovist)
(15, 16), which we show produces rapid, intense, and reversible
signal enhancement in T1-weighted MR images of cells expressing
the reporter in vivo. The reporter can produce more than twice as
much signal in vivo as MRI gene reporters described previously
(Table S1). Exchanging the gadolinium ion for the radionuclide
111In means, that in the same experiment, the Oatp1 reporter can
also be detected using SPECT, thus combining the spatial reso-
lution of MRI with the sensitivity of SPECT.
Results
First we demonstrated a quantitative relationship between Oatp1
expression and T1 relaxation enhancement in cells incubated
with Gd-EOB-DTPA (Fig. 1). Throughout the majority of the
studies reported here, the Oatp1 reporter transgene has either
been expressed from the relatively weak PGK promoter (17) and
the transgene introduced using lentiviral vectors (which have
single sites of integration), or by using a plasmid with the doxy-
cycline-inducible TRE3G promoter (maps of these constructs
are shown in Fig. S1). Human embryonic kidney cells (HEK
293T) and human colon adenocarcinoma cells (HCT 116) were
transfected with a doxycycline-inducible luciferase (Luc2)–Oatp1
construct (pTRE3G-LO), in which the coding sequences of Luc2
and Oatp1 were separated by an E2A sequence, which results in
equimolar production of the two proteins (18). The luciferase
provided a marker of transgene expression on Western blots in
these experiments. The increase in the relaxation rate (R1 = 1/
T1) (Fig. 1 A and B) was correlated with the increase in transgene
expression following induction with doxycycline (Fig. 1 C and D).
Induction of Oatp1 expression had no effect on the proliferation
rate of these cells (Fig. S2 A and B). Transport of hepatocyte-
specific MRI contrast agents by Oatp has been shown previously
to be specific, saturable, and bidirectional (19, 20). Reversible
transport was confirmed here by measurements of Gd-EOB-
DTPA uptake and washout in human breast cancer (MCF-7)
cells transfected with a vector expressing Oatp1 (Fig. S3). Con-
trast agent uptake in HEK 293T cells was dependent on the
contrast agent concentration and control cells showed no uptake
(Fig. S4).
Next we implanted, in the flanks of SCID mice, HEK 293T
cells expressing a luciferase–YFP fusion protein, which had been
transduced with an mStrawberry- and Oatp1-expressing lentiviral
vector (LV-PGK-SO; Fig. S1) and then subcloned. The two
coding sequences in this vector are separated by an E2A se-
quence. The same number of control luciferase–YFP-expressing
HEK 293T cells was implanted in the contralateral flanks. During
the 16 d following cell implantation, the resulting xenografts
expressing Oatp1 showed 5–12× greater light output than the
control xenografts (Fig. 2 A and B), suggesting that Oatp1 also
mediates transport of luciferin into cells. Luciferase–YFP was
equally expressed in the two cell lines, as assessed by the levels of
YFP fluorescence. Expression of Oatp1 was confirmed by im-
aging the red fluorescence from mStrawberry (Fig. 2A) and by
immunohistochemical staining for mStrawberry in histological
sections obtained postmortem (Fig. S5). These sections also
showed that there were low and similar levels of necrosis in these
xenografts (Fig. S5). Similar experiments were performed using
HCT 116 cells transfected with the doxycycline inducible vector
(pTRE3G-LO) that expressed the Luc2 and Oatp transgenes
(Fig. 1). There was increased bioluminescence in the transfected
cells measured 3 d after addition of doxycycline to the drinking
water (Fig. 2). These bioluminescence experiments demon-
strated that there was expression of Oatp1 in the HEK 293T and
HCT 116 xenografts in vivo and, in the case of the HEK 293T cells,
that the expressed transporter was functional. These experiments
also showed no evidence for an effect of Oatp1 expression on
xenograft growth.
Next we imaged these animals with MRI, using multislice
T1-weighted and T1 mapping pulse sequences before and fol-
lowing injection of 0.664 mmoles/kg of Gd-EOB-DTPA. This cor-
responds to a blood concentration of 8.3 mM, assuming a mouse
blood volume of 2 mL (21). There was no difference in T1 (or T2)
contrast in the MR images of control or contralateral Oatp1-
expressing xenografts before injection of the contrast agent
(Fig. 3 A and F), however following injection the spin lattice
relaxation rate R1 (1/T1) of Oatp1-expressing xenografts in-
creased by 2–4× (Fig. 3 B and G), which in the HEK 293T
xenografts resulted in an increase in pixel intensities of greater
than fourfold (Fig. 3 A and D). Assuming a molar relaxivity for
Gd-EOB-DTPA of 5.7 mM−1·s−1, this corresponds to a tissue con-
centration in the Oatp1-expressing HEK 293T xenografts of
0.32 mM. There was no significant change in contrast in control
xenografts or in muscle (Fig. 3 B and G). Contrast enhancement
in the Oatp1-expressing xenografts returned to baseline levels by
107 h for HEK 293T and by 60 h for HCT 116 (Fig. 3 B and G),
at which point we injected equimolar amounts of a control con-
trast agent, Gd-DTPA (Magnevist). This has a similar structure to
Gd-EOB-DTPA, but lacks the ethoxybenzene group and is not
a substrate for Oatp1. Gd-DTPA produced T1 contrast in both
Fig. 1. Relaxation enhancement rate (R1) correlates with Oatp1 expression.
(A) Clonal HEK 293T and (B) HCT 116 cells transfected with the inducible
pTRE3G-LO plasmid were induced for 24 h with doxycycline. Cells were then
incubated with 0.5 mM (HEK 293T) or 0.25 mM (HCT 116) Gd-EOB-DTPA,
washed, pelleted, and imaged with T1 imaging and mapping sequences.
Western blots of luciferase in protein extracts from (C) HEK 293T and (D)
HCT 116 cells shown in A and B, showing that induction of transgene ex-
pression correlated with doxycycline concentration and R1 enhancement.
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xenografts immediately following injection, and then rapidly
washed out, showing no significant signal enhancement in either
xenograft after 5 h (Fig. 3E and Fig. S6). Subsequent read-
ministration of Gd-EOB-DTPA showed enhancement of HEK
293T xenografts expressing Oatp1, but not the control xeno-
grafts, confirming the ability of the reporter to assess longitudi-
nal changes in gene expression (Fig. 3C). This also showed that
a maximum of 6.8-fold increase in signal was obtained in HEK
293T xenografts within 60 min of contrast agent administration.
The sensitivity of reporter expression can readily be increased by
using higher doses of contrast agent. For example, 2 mmoles/kg
of Gd-EOB-DTPA produced 7.8-fold more signal in an HEK
293T xenograft expressing Oatp1 than the control xenograft at
5 h postinjection. The agent has a median lethal dose of 10
mmol/kg when administered i.v. in mice and rats (22). Although
the levels of necrosis in these xenografts were relatively low (Fig.
S5), some of the early enhancement could be explained by ac-
cumulation of contrast agent in necrotic regions, however this
had cleared by 5 h after injection (Fig. S7). Contrast agent was
also, as expected, taken up by the liver (see whole mouse images
in Movie S1), which may preclude imaging of the reporter in and
around the liver. However, the degree of contrast enhancement
in the liver was comparable to that observed in the HEK
293T xenografts.
To demonstrate that Oatp1 could be used as a dual reporter
for radionuclide imaging, we replaced Gd3+ in the MRI con-
trast agent with 111In (111In-EOB-DTPA). Mice with control and
Oatp1-expressing HEK 293T xenografts, as used in the MRI
experiments (Fig. 3), were injected with 50–70 MBq of 111In-
EOB-DTPA and imaged using SPECT (Fig. 4). Xenografts
expressing Oatp1 contained 3.1-fold more of the injected dose
per gram tissue compared with control tumors at 1 h post-
injection, 7.8-fold more at 5 h, and 6.9-fold at 24 h (Fig. 4A).
SPECT-CT imaging at 1 and 5 h postinjection showed enhance-
ment in the Oatp1-expressing xenografts in comparison with
control xenografts, see Fig. 4 B and F. Enhancement of Oatp1-
expressing xenografts in both MR and SPECT images was dem-
onstrated, following sequential injections of Gd- EOB-DTPA
and 111In-EOB-DTPA, see Fig. 4 D–F. Background enhance-
ment of vasculature was visible on SPECT images at 1 h post-
injection, however this had cleared at the 5-h imaging time point.
Autoradiography of frozen tissue sections, which had been ex-
cised at 1 and 5-h post-111In-EOB-DTPA injection, demonstrated
a close correlation between tissue viability and 111In-EOB-DTPA
uptake in Oatp1-expressing tissue. There was 16.6-fold more 111In-
EOB-DTPA in viable regions of the Oatp1-expressing xenografts
than in viable regions of control tumors at 5-h postinjection
(Fig. S7).
Discussion
We have described a gene reporter that can be used with MRI
and radionuclide (SPECT) imaging. Exchanging Gd3+ for 68Ga
would also allow imaging with PET (23). As an MRI gene re-
porter the construct described here has a number of advantages
over those described previously. Detection is based on a Gd3+
contrast agent, which gives large positive contrast in T1-weighted
images and is easier to detect than the negative contrast gener-
ated by T2-agents, such as superparamagnetic iron oxide (SPIO)
nanoparticles (24) magA (25), and ferritin (26, 27). The contrast
agent is small, thus readily exiting the vasculature to gain access
to Oatp1-expressing cells, and because Oatps show restricted
tissue expression (28) background uptake in most tissues is
expected to be low (see a whole mouse with a Gd-EOB-DTPA–
enhanced xenograft in Movie S1). The observed relationship
between R1 and induction of Oatp1 expression indicates that the
kinetics of contrast agent uptake should give quantitative esti-
mates of gene expression levels. Finally, because Gd3+-based
hepatocyte-specific contrast agents have been approved for hu-
man use (15), and human OATP1B3 has been shown to take up
this contrast agent (16), this could facilitate transfer of this
technology to the clinic in the longer term.
The reporter may be particularly useful for tracking implanted
stem cells, because reporter detection should be unaffected by
cell division or exocytosis, which in the case of SPIO-based la-
beling causes dilution of the label (24, 29), and for interrogating
the differentiation state of the cells by incorporating tissue-spe-
cific promoters into the construct (30). The reporter could also
be used for monitoring the integration and expression of gene
therapy vectors (1). The combination of MRI and SPECT de-
tection with Gd-EOB-DTPA and 111In-EOB-DTPA, respectively,
may allow whole-body screening with SPECT, for detection of
labeled cell deposits, followed by more high-resolution and tar-
geted imaging with MRI.
Methods
Vector Construction.AnOatp1-expressing plasmid was constructed by cloning
a cDNA encoding Oatp1a1 (kindly provided by AllanWolkoff, Department of
Medicine, and Department of Anatomy and Structural Biology, Albert Einstein
College of Medicine, Bronx, NY, National Center for Biotechnology In-
formation, Nucleotide Database, reference sequence NM_017111.1) into pEF6-
V5/His A (Invitrogen). A 3,729-bp sequence encoding mStrawberry (4), E2A
(QCTNYALLKLAGDVESNPGP) (18), and Oatp1, with a stop codon at the end
of Oatp1, were cloned into the lentiviral transfer plasmid pBOBI (Inder
Fig. 2. Bioluminescence measurements demonstrate expression of Oatp1 in vivo. (A) Light output was greater in the bioluminescence image (BLI) from the
Oatp1-expressing HEK 293T xenograft (right flank), whereas luciferase–YFP fluorescence was the same in both xenografts. Red fluorescence confirmed ex-
pression of the mStrawberry–Oatp1 transgenes. (B) Mean increase in light output from Oatp1-expressing xenografts compared with controls expressing
luciferase–YFP alone (n = 5). Points represent the average light output over 20 min following i.p. injection of luciferin. Error bars show SEM. (C) Light output
was increased from a representative HCT 116 tumor expressing an inducible luciferase–E2A–Oatp1 construct, 3 d postinduction with doxycycline (10 mg/mL in
drinking water), compared with the control tumor (left flank), which was not transfected with the construct.











M. Verma laboratory, Salk Institute, La Jolla, CA) 3′ to a 500-bp PGK promoter
(17) (referred to as “LV-PGK-SO”). Replication-defective vesicular stomatitis
virus glycoprotein-pseudotyped lentiviral vectors were produced (31), and
purified (32) according to published protocols, using the transfer plasmids
and three packaging plasmids (Inder M. Verma laboratory). Inducible plas-
mids were produced using a doxycycline responsive promoter (TRE3G): one
with the mStrawberry–E2A–Oatp sequence described above and one with
mStrawberry replaced by the luciferase (Luc2)-coding sequence (referred
to as “pTRE3G-SO” and “pTRE3G-LO”).
Animal Experiments. Female SCID mice were obtained from Charles River at
∼20 g (2–3 mo) and used within a few months of acquisition. Animals were
injected s.c. with 1 × 107 viable cells per flank and anesthetized using 2%
Isofluorane in 75% air/25% O2 (vol/vol; flow rate, 2 L/min) for bioluminescence,
fluorescence, radionuclide, and MRI experiments. Animal experiments were
carried out under the authority of project and personal licenses issued by the
Home Office of the United Kingdom and had been subject to ethical review
by the Cancer Research UK, Cambridge Institute Animal Welfare and Ethical
Review Body.
Cell Culture. HEK 293T cells were acquired from Thermo Scientific, breast
adenocarcinoma cells (MCF-7) from the European Collection of Animal Cell
Cultures (Teddington, UK) and HCT 116 cells from LGC Promochem. All cells
were grown in DMEM (Invitrogen), supplemented with 10% (vol/vol) FBS,
Fig. 3. MRI of Oatp1 expression in vivo. (A) T1-weighted images before (0 h) and 5, 10, 25, 50, and 80 h after i.v. injection of Gd-EOB-DTPA, from a repre-
sentative animal bearing an HEK 293T xenograft (as shown in Fig. 2). Control xenografts (left flank) expressed luciferase–YFP and the xenografts on the right
flank also expressed Oatp1. (B) Xenograft relaxation rates (R1) before (0 h) and following i.v. injection of Gd-EOB-DTPA (0.664 mmoles/kg) were significantly
greater compared with controls [*P < 0.001, **P < 0.0001, n = 5 (n = 4 at 107 h)]. (C) R1 increased in control and Oatp1-expressing xenografts after repeat i.v.
injection with Gd-EOB-DTPA (0.664 mmoles/kg), following washout of the original dose in B and injection and washout of Gd-DTPA (E) (n = 2). Error bars show
SEM. (D) Pixel intensities along a line bisecting the control and Oatp1-expressing xenografts shown in A, obtained before (0 h) and 5 h after Gd-EOB-DTPA
injection. (E) The same as in D, but before (0 h) and 5 h after injection of Gd-DTPA. (F) T1-weighted images before (0 h) and 1, 5, 10, 23, and 60 h after i.v.
injection of Gd-EOB-DTPA (0.664 mmoles/kg) from a representative mouse bearing a control HCT 116 xenograft (left flank) and a xenograft expressing the
pTRE3G-LO construct (right flank). Animals were induced with 10 mg/mL doxycycline in the drinking water for 3 d before imaging. (G) Relaxation rates (R1)
before (0 h) and following i.v. injection of Gd-EOB-DTPA. R1 was significantly greater in xenografts expressing Oatp1 compared with controls (one-tailed paired
t test, *P < 0.05, **P < 0.01, ***P < 0.005, n = 4 at 0–24 h, n = 3 at 60 h). Error bars show the SEM. Some error bars are obscured by the data points.
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2 mM L-glutamine, and 0.1 mM MEM nonessential amino acids, except
HCT 116 cells, which were grown in McCoy’s 5A GlutaMAX media (Invitrogen),
supplemented with 10% (vol/vol) FBS. Cells were mycoplasma tested upon re-
ceipt. Additionally, before experimentation, HEK 293T and HCT 116 cells were
genotyped using AmpFISTR profiling (Invitrogen), with HCT 116 cells having
94% identity with the American Type Culture Collection profile, and HEK 293T
cells having 88% identity.
Cell Transfection and Transduction. pEF6-Oatp1a1 and pEF6-V5/His A were
linearized with Fsp I and transfected into MCF-7 cells seeded at a density of
1 × 104 cells per cm2 using FuGene (Roche). Transfected cells were selected
using Blasticidin (15 μg/mL) and cloned. HEK 293T cells were transduced with
a feline immunodeficiency virus-based vector (33) encoding a Luc2–YFP fu-
sion protein under a CMV promoter. Transgene-expressing clones were se-
lected using hygromycin. Stable clones from lentivirus-infected cells were
expanded from single cells, following plating out at low seeding densities.
Expression of the transgenes was confirmed by Western blot and by flow
cytometry (FACSCalibur II) or fluorescence imaging (IVIS 200 series camera;
Caliper Life Sciences) or by microscopy. The doxycycline-inducible luciferase–
E2A–Oatp1 and mStrawberry–E2A–Oatp1 plasmids used for MRI and radio-
nuclide experiments in vivo and the MRI in vitro, were constructed using
a modified TRE3G vector (Clontech) containing a puromycin resistance cas-
sette for selection of stable clones.
Cell Uptake Experiments. MCF-7 cells were seeded at 1.2 × 105 cells per cm2
and after ∼24 h were washed with transport buffer (142 mM NaCl, 5 mM
KCl, 1 mM KH2PO4, 1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM D-glucose, 12.2 mM
Hepes, pH 7.3) and incubated with 5 mM Gd-EOB-DTPA (Bayer) at 37 °C,
5% CO2. After incubation, cells were washed and lysed with Nonidet P-40.
HEK 293T and HCT 116 cells expressing luciferase–YFP and cells expressing
mStrawberry–OATP, were grown to ∼80% confluence and incubated with or
without Gd-EOB-DTPA (0.25 mM, 0.5 mM) in the growth media for 90 min.
The media was then removed and the cells washed twice in PBS. Cells were
then trypsinized, pelleted in 1.5-mL Eppendorf centrifuge tubes, the su-
pernatant removed, and T1 of the pellets determined using a T1 imaging
experiment at 7 T.
Western Blots. Cells were extracted using M-Per reagent (Thermo Scientific)
with Complete Mini Protease inhibitors (Roche), and protein concentration
determined using the Bradford assay. Extracts were run on an SDS PAGE gel
(NuPAGE, Invitrogen), transferred to a nitrocellulose membrane and lucif-
erase–YFP detected using polyclonal goat anti-luciferase antibody (g475A,
Promega), at 1 in 25,000 dilution with incubation for 1 h at room temper-
ature. For α-tubulin staining, a monoclonal mouse anti–α-tubulin (T1799,
Sigma-Aldrich) was used at 1 in 1,000 dilution with overnight incubation at
4 °C. For mStrawberry staining, rabbit polyclonal anti-RFP (ab34771, AbCam)
was used at 1 in 10,000 dilution with overnight incubation at 4 °C. Horseradish
peroxidase-conjugated anti-rabbit (111-035-003), anti-goat (705-035-003-JIR),
and anti-mouse (115-035-006-JIR) antibodies (Jackson Immunoresearch) were
used as the secondary antibodies at 1 in 10,000 dilution with an incubation
time of 45 min at room temperature. All antibodies were diluted with 5% (wt/
vol) milk powder and 0.1% Tween.
Fluorescence and Bioluminescence Imaging. Images were acquired using an
IVIS 200 series camera (Perkin-Elmer) with an F-stop of 1 and exposure of 60 s.
RFP imaging was performed with excitation wavelengths between 580 and
610 nmand emissionwavelengths between 615 and 665 nm, andYFP imaging
with excitations between 480 and 520 nm and emission between 525 and
560 nm. Before fluorescence imaging, mice were shaved around the site of
cell implantation. Regions of interest were analyzed using Living Image
software (Perkin-Elmer).
MRI. Images were acquired using a 7-T horizontal system and VnmrJ software
(Agilent). T1-weighted spin-echo images (14 slices 1.5 mm thick) were acquired
Fig. 4. Oatp1 expression was detectable in HEK 293T xenografts using MRI and SPECT after sequential injections of Gd-EOB-DTPA and 111In-EOB-DTPA,
respectively. (A) Measurements on extracted tissue showed that 111In-EOB-DTPA was taken up by Oatp1-expressing xenografts (n = 3, two-tailed t test, **P <
0.01). (B) SPECT-CT image obtained 5 h after injection of 111In-EOB-DTPA. The xenograft on the left flank was a control and the xenograft on the right flank
expressed Oatp1. (C) CT image showing control (left flank) and Oatp1-expressing (right flank) xenografts. (D) T1-weighted MR image of the section shown in
C, 1 h postinjection of Gd-EOB-DTPA. (E) SPECT image of the cross section shown in C, 1 h postinjection of 111In-EOB-DTPA. (F) MRI and SPECT images shown in
D and E combined.











with an echo time of 8 ms, repetition time of 400 ms, 50 × 50 mm2 field of view
(FOV), 256 × 128 resolution, and four averages per increment. T1 maps were
acquired using an inversion recovery fast low angle shot pulse sequence with
eight inversion times between 0.05 s and 6.4 s, repetition time (TR) 4.46 ms,
echo time (TE) 2.1 ms, 12-s delay between images, resolution 128 × 64, FOV
of 60 × 60 mm, slice thickness of 2 mm, two averages per increment, and
a flip angle of 10°. Gd3+-chelate concentration in cell lysates was de-
termined by measuring the T1 relaxation time at 9.4 T using an inversion
recovery pulse sequence with seven inversion times between 0.25 s and 16 s.
Whole-body acquisitions were performed using a 3D gradient-echo pulse
sequence (TR 20 ms, TE 3 ms, flip angle 20°, FOV 76.8 × 38.4 × 25.6 mm,
data matrix 384 × 192 × 128).
SPECT Imaging. SPECT imaging was performed using a NanoSPECT system
(Bioscan Inc.), and CT was performed using a microtomography system
(NanoPET/CT; Mediso). SPECT apertures of 2 mm were used with a scan time
of 1 h. Images were reconstructed and data analyzed using Vivoquant 1.42
software (InviCRO).
Histology. Following MRI, tissues were excised and fixed in 10% formalin in
PBS for 24 h, then changed into ethanol, and paraffin embedded. Sections
6 μm thick were cut and stained with hematoxylin/eosin (H&E). RFP was
stained with rabbit polyclonal anti-RFP (ab34771, AbCam), at 1 in 500 di-
lution at 4 °C overnight and developed using ABC Vectastain and DAB
peroxidase kits according to the manufacturer’s instructions (Vectorlabs).
Slides were scanned using a Scanscope XT (Aperio). Following 111In-EOB-
DTPA injection, excised xenografts were frozen on dry ice and sectioned (10
μm) at −20 °C in a cryostat (CM3050S Cryostat; Leica). Sections were thaw
mounted onto microscope slides and air dried before placing next to
a storage phosphor screen for 1 wk (BAS-IP MS 2040; GE Healthcare). Slides
were then stained with H&E. Phosphor screens were imaged on a Typhoon
Trio+ (GE Healthcare) at pixel size of 25 μm. Images were analyzed using
ImageJ software (National Institutes of Health).
Statistical Analyses. Student’s t test and linear regression were performed
using Excel (Microsoft) and Graphpad Prism (Graphpad Software Inc.) soft-
ware. All t tests were calculated to find an effect size of 3.5 (Cohen’s d)
between populations with a P ≤ 0.05 using three biological replicates per
condition, with a power of 80%, assuming a normal distribution. Unequal
variance t tests were used when variance between groups was not similar.
No blinding or randomization were used in any of the experiments, and no
animals were excluded from analyses.
Production of 111In-EOB-DTPA. Primovist (Bayer) was diluted to 0.1 M in a 0.4-M
solution of oxalate dihydrate. The precipitate was removed by centrifugation
and the supernatant passed through a syringe column (Oasis HLB, 225-mg resin;
Waters), which had been preflushedwith 1mL ethanol and 10mLwater. Excess
oxalate was eluted with 10 mL water, then the gadolinium-free chelate was
eluted with 5 mL 10% ethanol and vacuum dried. Identity of the chelate and
labeling with cold indium were confirmed by mass spectrometry. Labeling was
performed in 0.1 M ammonium acetate buffer (pH 7), in which the chelate was
dissolved at 1.5 mg/mL and mixed with 111In at a ratio of 2:1, reducing the pH
to 6. Labeling was assessed at 98%, using HPLC and TLC, after 10 min in-
cubation at room temperature.
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